Global GLP-1 Analogues Market
Summary:
This report presents detailed information on glucagon-like peptide-1 (GLP-1) analogues. It examines market trends for GLP-1 analogues using data from 2024, estimates for 2025, and projected compound annual growth rates (CAGRs) through 2030 (the forecast period of 2025–2030). The report also covers regional markets for GLP-1 analogues. The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025–2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.
The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.
Report Scope
This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025–2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.
The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.
The report aims to:
Report Includes
This report presents detailed information on glucagon-like peptide-1 (GLP-1) analogues. It examines market trends for GLP-1 analogues using data from 2024, estimates for 2025, and projected compound annual growth rates (CAGRs) through 2030 (the forecast period of 2025–2030). The report also covers regional markets for GLP-1 analogues. The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025–2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.
The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.
Report Scope
This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025–2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.
The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.
The report aims to:
- Analyze the market for GLP-1 analogues.
- Analyze the global market size and market segments.
- Understand market constraints and drivers.
- Provide detailed market forecasts for 2030.
- Assess market share, competitiveness and industry structure.
- Identify potential long-term impacts on the GLP-1 analogue market.
Report Includes
- An overview of the current and future global markets for GLP-1 analogues
- In-depth analysis of global market trends, featuring historical revenue data for 2022–2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Estimates of the size and revenue prospects of the global market, along with a market share analysis by route of administration, indication and region
- Facts and figures pertaining to the market dynamics, technical advances, regulations and the impact of macroeconomic factors
- An analysis of patents, emerging trends and developments in the industry
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Profiles of the leading companies
CHAPTER 1 EXECUTIVE SUMMARY
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
CHAPTER 2 MARKET OVERVIEW
Overview
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Market Demand and Demographics
Porter's Five Forces Analysis
Bargaining Power of Buyers (High)
Bargaining Power of Suppliers (Moderate to High)
Potential for New Entrants (Low)
Threat of Substitutes (Moderate)
Competitiveness in the Industry (High)
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Increasing Cases of Diabetes and Obesity
Increasing Awareness of Diagnosis and Treatment Options for Diabetes
Strong R&D Pipeline
Market Restraints
Product Failure
High Barriers for New Entrants
Market Opportunities
Extended Therapeutic Uses
Integration in Telehealth and Weight Management Program
CHAPTER 4 REGULATORY LANDSCAPE
Regulatory Dynamics
U.S.
Europe
Japan
China
CHAPTER 5 EMERGING TECHNOLOGIES AND PIPELINE ANALYSIS
Emerging Trends/Technologies
Next-Generation Multi-Receptor Agonists
Innovative Drug Delivery Methods
Expanded Therapeutic Indications
Pipeline Analysis
Key Takeaways
Patent Analysis
Key Takeaways
CHAPTER 6 MARKET SEGMENT ANALYSIS
Segmentation Breakdown
Global GLP-1 Analogues Market by Route of Administration
Key Takeaways
Injectable
Oral
Geographic Breakdown
Global GLP-1 Analogue Market by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
CHAPTER 7 COMPETITIVE INTELLIGENCE
Key Takeaways
Competitive Landscape
Company Share Analysis
CHAPTER 8 SUSTAINABILITY IN GLP-1 ANALOGUES: ESG PERSPECTIVE
Introduction to ESG
Sustainability in the GLP-1 Analogue Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
Conclusion
CHAPTER 9 APPENDIX
Methodology
Sources
Abbreviations
Company Profiles
HANSOH PHARMACEUTICAL GROUP CO. LTD.
LILLY USA LLC.
NOVO NORDISK A/S
SANOFI
SHANGHAI BENEMAE PHARMACEUTICAL CORP.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Players
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
CHAPTER 2 MARKET OVERVIEW
Overview
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Market Demand and Demographics
Porter's Five Forces Analysis
Bargaining Power of Buyers (High)
Bargaining Power of Suppliers (Moderate to High)
Potential for New Entrants (Low)
Threat of Substitutes (Moderate)
Competitiveness in the Industry (High)
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Increasing Cases of Diabetes and Obesity
Increasing Awareness of Diagnosis and Treatment Options for Diabetes
Strong R&D Pipeline
Market Restraints
Product Failure
High Barriers for New Entrants
Market Opportunities
Extended Therapeutic Uses
Integration in Telehealth and Weight Management Program
CHAPTER 4 REGULATORY LANDSCAPE
Regulatory Dynamics
U.S.
Europe
Japan
China
CHAPTER 5 EMERGING TECHNOLOGIES AND PIPELINE ANALYSIS
Emerging Trends/Technologies
Next-Generation Multi-Receptor Agonists
Innovative Drug Delivery Methods
Expanded Therapeutic Indications
Pipeline Analysis
Key Takeaways
Patent Analysis
Key Takeaways
CHAPTER 6 MARKET SEGMENT ANALYSIS
Segmentation Breakdown
Global GLP-1 Analogues Market by Route of Administration
Key Takeaways
Injectable
Oral
Geographic Breakdown
Global GLP-1 Analogue Market by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
CHAPTER 7 COMPETITIVE INTELLIGENCE
Key Takeaways
Competitive Landscape
Company Share Analysis
CHAPTER 8 SUSTAINABILITY IN GLP-1 ANALOGUES: ESG PERSPECTIVE
Introduction to ESG
Sustainability in the GLP-1 Analogue Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
Conclusion
CHAPTER 9 APPENDIX
Methodology
Sources
Abbreviations
Company Profiles
HANSOH PHARMACEUTICAL GROUP CO. LTD.
LILLY USA LLC.
NOVO NORDISK A/S
SANOFI
SHANGHAI BENEMAE PHARMACEUTICAL CORP.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Players
LIST OF TABLES
Summary Table : Global Market for GLP-1 Analogues, by Region, Through 2030
Table 1 : Global Health Expenditure, by Selected Country, 2021–2023
Table 2 : Worldwide Diabetic Adult Population , by Region, 2000–2050(Thousands)
Table 3 : FDA-Approved GLP-1 Receptor Agonists
Table 4 : Selected Clinical Trials for GLP-1 Receptor Agonists in Phases 3 and 4
Table 5 : Selected Granted Patents Related to GLP-1 Analogues, 2022–2024
Table 6 : Global Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 7 : Global Market for Injectable GLP-1 Analogues, by Region, Through 2030
Table 8 : Global Market for Oral GLP-1 Analogues, by Region, Through 2030
Table 9 : Global Market for GLP-1 Analogues, by Region, Through 2030
Table 10 : North American Diabetes Statistics and Prevalence, 2011–2050
Table 11 : North American Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 12 : North American Market for GLP-1 Analogues, by Country, Through 2030
Table 13 : European Diabetes Statistics and Prevalence, 2011–2050
Table 14 : European Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 15 : European Market for GLP-1 Analogues, by Country, Through 2030
Table 16 : South East Asian Diabetes Statistics and Prevalence, 2011–2050
Table 17 : Asia-Pacific Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 18 : Asia-Pacific Market for GLP-1 Analogues, by Country, Through 2030
Table 19 : South and Central American Diabetes Statistics and Prevalence, 2011–2050
Table 20 : South American Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 21 : South American Market for GLP-1 Analogues, by Country, Through 2030
Table 22 : Middle East and North Africa Diabetes Statistics and Prevalence, 2011–2050
Table 23 : MEA Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 24 : MEA Market for GLP-1 Analogues, by Sub-Region, Through 2030
Table 25 : Product Revenue, by Company, 2023 and 2024
Table 26 : Information Sources for this Report
Table 27 : Abbreviations Used in this Report
Table 28 : Hansoh Pharmaceutical Group Co. Ltd.: Company Snapshot
Table 29 : Hansoh Pharmaceutical Group Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 30 : Hansoh Pharmaceutical Group Co. Ltd.: Product Portfolio
Table 31 : Hansoh Pharmaceutical Group Co. Ltd.: News/Key Developments, 2025
Table 32 : Lilly USA LLC.: Company Snapshot
Table 33 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 34 : Lilly USA LLC.: Product Portfolio
Table 35 : Lilly USA LLC.: News/Key Developments, 2025
Table 36 : Novo Nordisk A/S: Company Snapshot
Table 37 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 38 : Novo Nordisk A/S: Product Portfolio
Table 39 : Novo Nordisk A/S: News/Key Developments, 2023–2025
Table 40 : Sanofi: Company Snapshot
Table 41 : Sanofi: Financial Performance, FY 2023 and 2024
Table 42 : Sanofi: Product Portfolio
Table 43 : Sanofi: News/Key Developments, 2024
Table 44 : Shanghai Benemae Pharmaceutical Corp.: Company Snapshot
Table 45 : Shanghai Benemae Pharmaceutical Corp.: Product Portfolio
Table 46 : Shanghai Benemae Pharmaceutical Corp.: News/Key Developments, 2023
Table 47 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 48 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 49 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 50 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2024 and 2025
Table 51 : Few Emerging Players in the GLP1 Analogue Market
Summary Table : Global Market for GLP-1 Analogues, by Region, Through 2030
Table 1 : Global Health Expenditure, by Selected Country, 2021–2023
Table 2 : Worldwide Diabetic Adult Population , by Region, 2000–2050(Thousands)
Table 3 : FDA-Approved GLP-1 Receptor Agonists
Table 4 : Selected Clinical Trials for GLP-1 Receptor Agonists in Phases 3 and 4
Table 5 : Selected Granted Patents Related to GLP-1 Analogues, 2022–2024
Table 6 : Global Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 7 : Global Market for Injectable GLP-1 Analogues, by Region, Through 2030
Table 8 : Global Market for Oral GLP-1 Analogues, by Region, Through 2030
Table 9 : Global Market for GLP-1 Analogues, by Region, Through 2030
Table 10 : North American Diabetes Statistics and Prevalence, 2011–2050
Table 11 : North American Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 12 : North American Market for GLP-1 Analogues, by Country, Through 2030
Table 13 : European Diabetes Statistics and Prevalence, 2011–2050
Table 14 : European Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 15 : European Market for GLP-1 Analogues, by Country, Through 2030
Table 16 : South East Asian Diabetes Statistics and Prevalence, 2011–2050
Table 17 : Asia-Pacific Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 18 : Asia-Pacific Market for GLP-1 Analogues, by Country, Through 2030
Table 19 : South and Central American Diabetes Statistics and Prevalence, 2011–2050
Table 20 : South American Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 21 : South American Market for GLP-1 Analogues, by Country, Through 2030
Table 22 : Middle East and North Africa Diabetes Statistics and Prevalence, 2011–2050
Table 23 : MEA Market for GLP-1 Analogues, by Route of Administration, Through 2030
Table 24 : MEA Market for GLP-1 Analogues, by Sub-Region, Through 2030
Table 25 : Product Revenue, by Company, 2023 and 2024
Table 26 : Information Sources for this Report
Table 27 : Abbreviations Used in this Report
Table 28 : Hansoh Pharmaceutical Group Co. Ltd.: Company Snapshot
Table 29 : Hansoh Pharmaceutical Group Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 30 : Hansoh Pharmaceutical Group Co. Ltd.: Product Portfolio
Table 31 : Hansoh Pharmaceutical Group Co. Ltd.: News/Key Developments, 2025
Table 32 : Lilly USA LLC.: Company Snapshot
Table 33 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 34 : Lilly USA LLC.: Product Portfolio
Table 35 : Lilly USA LLC.: News/Key Developments, 2025
Table 36 : Novo Nordisk A/S: Company Snapshot
Table 37 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 38 : Novo Nordisk A/S: Product Portfolio
Table 39 : Novo Nordisk A/S: News/Key Developments, 2023–2025
Table 40 : Sanofi: Company Snapshot
Table 41 : Sanofi: Financial Performance, FY 2023 and 2024
Table 42 : Sanofi: Product Portfolio
Table 43 : Sanofi: News/Key Developments, 2024
Table 44 : Shanghai Benemae Pharmaceutical Corp.: Company Snapshot
Table 45 : Shanghai Benemae Pharmaceutical Corp.: Product Portfolio
Table 46 : Shanghai Benemae Pharmaceutical Corp.: News/Key Developments, 2023
Table 47 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 48 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 49 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 50 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2024 and 2025
Table 51 : Few Emerging Players in the GLP1 Analogue Market
LIST OF FIGURES
Summary Figure : Global Market Shares of GLP-1 Analogues, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis of the GLP-1 Analogue Market
Figure 2 : Market Dynamics of GLP-1 Analogues
Figure 3 : Clinical Trial Studies of GLP-1 Drugs, by Trial Phase, 2022–2025*
Figure 4 : Global Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 5 : Global Market Shares of Injectable GLP-1 Analogues, by Region, 2024
Figure 6 : Global Market Shares of Oral GLP-1 Analogues, by Region, 2024
Figure 7 : Global Market Shares of GLP-1 Analogues, by Region, 2024
Figure 8 : North American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 9 : North American Market Shares of GLP-1 Analogues, by Country, 2024
Figure 10 : European Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 11 : European Market Shares of GLP-1 Analogues, by Country, 2024
Figure 12 : Asia-Pacific Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 13 : Asia-Pacific Market Shares of GLP-1 Analogues, by Country, 2024
Figure 14 : South American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 15 : South American Market Shares of GLP-1 Analogues, by Country, 2024
Figure 16 : MEA Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 17 : MEA Market Shares of GLP-1 Analogues, by Sub-Region, 2024
Figure 18 : Global Market Shares of GLP-1 Analogues, by Company, 2024
Figure 19 : Pillars of ESG
Figure 20 : Advantages of ESG for Companies
Figure 21 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 22 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
Figure 23 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2024
Figure 24 : SANOFI: Revenue Share, by Country/Region, FY 2024
Figure 25 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2024
Figure 26 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, 2024
Summary Figure : Global Market Shares of GLP-1 Analogues, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis of the GLP-1 Analogue Market
Figure 2 : Market Dynamics of GLP-1 Analogues
Figure 3 : Clinical Trial Studies of GLP-1 Drugs, by Trial Phase, 2022–2025*
Figure 4 : Global Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 5 : Global Market Shares of Injectable GLP-1 Analogues, by Region, 2024
Figure 6 : Global Market Shares of Oral GLP-1 Analogues, by Region, 2024
Figure 7 : Global Market Shares of GLP-1 Analogues, by Region, 2024
Figure 8 : North American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 9 : North American Market Shares of GLP-1 Analogues, by Country, 2024
Figure 10 : European Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 11 : European Market Shares of GLP-1 Analogues, by Country, 2024
Figure 12 : Asia-Pacific Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 13 : Asia-Pacific Market Shares of GLP-1 Analogues, by Country, 2024
Figure 14 : South American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 15 : South American Market Shares of GLP-1 Analogues, by Country, 2024
Figure 16 : MEA Market Shares of GLP-1 Analogues, by Route of Administration, 2024
Figure 17 : MEA Market Shares of GLP-1 Analogues, by Sub-Region, 2024
Figure 18 : Global Market Shares of GLP-1 Analogues, by Company, 2024
Figure 19 : Pillars of ESG
Figure 20 : Advantages of ESG for Companies
Figure 21 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 22 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
Figure 23 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2024
Figure 24 : SANOFI: Revenue Share, by Country/Region, FY 2024
Figure 25 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2024
Figure 26 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, 2024
